Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities researchers at HC Wainwright upped their Q2 2025 earnings estimates for shares of Kamada in a report issued on Friday, May 16th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of $0.11 for the quarter, up from their previous estimate of $0.06. HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada's FY2026 earnings at $0.42 EPS.
KMDA has been the topic of several other reports. Benchmark restated a "buy" rating and set a $15.00 price objective on shares of Kamada in a research note on Thursday. Sidoti upgraded Kamada to a "hold" rating in a research note on Thursday, May 8th. Finally, StockNews.com cut Kamada from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, March 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $14.67.
View Our Latest Stock Analysis on KMDA
Kamada Trading Up 1.2%
Shares of NASDAQ:KMDA opened at $6.94 on Monday. The stock's fifty day simple moving average is $6.60 and its two-hundred day simple moving average is $6.60. Kamada has a 1-year low of $4.74 and a 1-year high of $9.16. The stock has a market cap of $398.91 million, a PE ratio of 24.79, a price-to-earnings-growth ratio of 0.97 and a beta of 0.94.
Kamada (NASDAQ:KMDA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. Kamada had a net margin of 9.92% and a return on equity of 6.30%. The business had revenue of $44.02 million during the quarter, compared to the consensus estimate of $154.06 million.
Institutional Investors Weigh In On Kamada
Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in shares of Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 1,549 shares during the period. JPMorgan Chase & Co. bought a new stake in Kamada in the 4th quarter valued at about $67,000. Aristides Capital LLC raised its stake in Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after acquiring an additional 6,850 shares during the period. NewEdge Advisors LLC raised its stake in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after acquiring an additional 8,260 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in Kamada in the 1st quarter valued at about $497,000. 20.38% of the stock is currently owned by institutional investors.
Kamada Announces Dividend
The firm also recently announced a -- dividend, which was paid on Monday, April 7th. Stockholders of record on Monday, March 17th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, March 17th.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
